Currently many drugs are still designed as “ one-pill-fits-all” but they don’t work the same for individuals. Adverse drug reactions is often seen in individuals who don’t respond well to such drugs. Hence it is important to understand the differences in the genes that affect the body’s response to drugs.

CromDx has developed a wide range of pharmacogenomics tests to help physicians in prognosis, therapy selection and monitoring of diseases. Using the test results physicians can infer wheather the treatment is necessary or predict the efficacy/safety response to specific treatments.

CromDx laboratory is a highly equipped clinical genomics testing facility offering a wide range of genomic tests. The diagnostics arm has launched important screening and diagnosis tests to help physicians nip disease in the bud. Specialists can use these tests for definitive diagnosis and follow-up with appropriate treatment. Individuals can benefit vastly by identifying the right nature of the diseases early to avoid costly treatments and disease burden at later stage.



Drugs used to treat cardiovascular conditions are among the most widely prescribed therapies worldwide. Adverse events arising from wrongly prescribed drugs or dosages especially patients undergoing angioplasty or heart valve surgeries can lead to complex events requiring costly interventions later or even death. Popular Anti-coagulant such as Warfarin and anti-platelet such as Clopidogrel show highly variable response among Asians and hence DNA testing to determine the metabolizer status or the personalized dosage is recommended.

Test ID Test Description TAT
 CRX-CA-0001  CromCP - Clopidogrel resistance PGx Test  4 days
 CRX-CA-0002  CromSTAT - PGx test to determine optimal dosage of Statins  4 days
 CRX-CA-0003  CromWAC - PGx test to determine Warfarin/Acenocoumarol dosage  4 days
 CRX-CA-0004  CromPGxmini panel - test to determine Clopidogrel, Statins and Warfarin optimal dosages  5 days



Pharmacogenomics testing in Oncology has changed the paradigm of treatment decisions. While variety of treatments are available, a number of patients still experience serious adverse events while some of the others don’t receive the theraupeutic benefits. Targeted and individualized therapy using pharmacogenomics testing helps improve the outcomes for a patient and also cuts the hospitalization costs significantly.

Test ID Test Description TAT
 CRX-OC-0001 EGFR Mutation Testing in response to TKI (Tyrosine Kinase Inhibitors) Gefitinib & Erlotininb
 5 days
 CRX-OC-0002 KRAS Mutation Testing in response to Cetuximab and Panitumumab and Reflex to BRAF Codon 600 Mutation Detection  5 days
 CRX-OC-0003 NRAS Mutation Testing in response to Cetuximab and Panitumumab therapies

 5 days
 CRX-OC-0005 BRAF Mutation Testing in melanoma and colorectal cancer to determine responsiveness to anti-EGFR therapies : Cetuximab and Panitumumab
 5 days



Immunosuppressants are widely used to prevent acute rejection following solid-organ transplantation such as kidney, heart and liver. Several investigations have shown that genetic variations in CYP3A5 gene explain a part of the "between-patient" variability in the pharmacokinetics of immunosuppresants. Individualized dose based on the patient’s genotype, help in lowering chances of transplant rejection.

Test ID Test Description TAT
 CRX-OT-0001 TACrom - Tacrolimus sensitivity by Genotyping and dosage optimization in organ transplant
 5 days